COVID-19: Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: THOMAS  DENNY
Organization: DUKE UNIVERSITY
Fiscal Year: 2020
Award: $573,990
Funding agency: National Institute of Allergy and Infectious Diseases

The NIAID Division of AIDS has a requirement for the conduct of quantitative viral RNA measurements for assessment of HIV/SIV vaccine efficacy in preclinical studies with nonhuman primates. The NIAID provides immunological and virological support for nonhuman primate studies conducted at NIAID’s Simian Vaccine Evaluation Unit contract sites (SVEUs) and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development, previously called the NHP “Core Laboratories.” The objective of the Core Laboratories has been to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines.  This project will support the performance of viral RNA assays in support of animal studies evaluating SARS CoV-2 vaccine and therapeutic products.

Terms: <2019 novel coronavirus><2019-nCoV><AIDS><AIDS Vaccines><AIDS vaccine><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunologic Deficiency Syndrome><Animals><Assay><Bioassay><Biologic Assays><Biological Assay><COVID-19><COVID19><Contracting Opportunities><Contracts><Development and Research><Ensure><HIV/SIV vaccine><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunology><Investigators><Laboratories><Measurement><NIAID><National Institute of Allergy and Infectious Disease><Performance><R & D><R&D><Research Personnel><Researchers><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><Site><Standardization><Therapeutic><Vaccines><Wuhan coronavirus><corona virus disease 2019><coronavirus disease 2019><immunogenicity><non-human primate><nonhuman primate><pre-clinical><pre-clinical study><preclinical><preclinical study><research and development><vaccine efficacy><vaccine evaluation><vaccine screening><vaccine testing><viral RNA><virology><virus RNA>